Vaccines, In Brief: Meningitis B Recommendation Limited To High-Risk Groups
This article was originally published in The Pink Sheet Daily
Executive Summary
Also, CDC advisory committee withdraws preferred status for AstraZeneca’s FluMist in children and adds Merck’s Gardasil 9 to recommendations for HPV vaccination.
You may also be interested in...
Merck’s Gardasil Adds Serotypes; Boosting Vaccinations Seems Bigger Challenge
Promotion strategy likely to remain same after nine-valent HPV vaccine wins FDA approval; Merck may need help from the CDC to overcome cultural barriers to adoption.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.